

# Human Monoclonal Antibodies for the Therapy of Transthyretin Amyloidosis Diseases

<https://neurodegenerationresearch.eu/survey/human-monoclonal-antibodies-for-the-therapy-of-transthyretin-amyloidosis-diseases/>

## Principal Investigators

Ole Suhr

## Institution

Umeå University

## Contact information of lead PI

### Country

Sweden

## Title of project or programme

Human Monoclonal Antibodies for the Therapy of Transthyretin Amyloidosis Diseases

## Source of funding information

VINNOVA

## Total sum awarded (Euro)

€ 47,080

## Start date of award

01/09/2014

## Total duration of award in years

2

## Keywords

### Research Abstract

Transthyretin (TTR) amyloidosis is a fatal disease caused by deposition of TTR amyloid (ATTR) fibrils in various organs, such as the heart and nerves leading to organ damage and dysfunction. TTR is a tetramer, and the current concept for ATTR is that the tetramer dissociates into monomers that after conformational changes miss-folds and reassemble as amyloid fibrils. Two different forms of the disease is recognised: 1, where the dissociation of the tetramer is facilitated by a TTR mutation (h-ATTR amyloidosis), and 2, where ageing facilitate dissociation of wild type TTR (wt-ATTR amyloidosis). The treatment available today is liver transplantation for patients with h-ATTR amyloidosis aiming at exchanging the variant TTR

producing liver with one that produces wt-TTR. In addition, TTR stabilising agents have been developed to prevent dissociation of tetrameric TTR, however, no available treatment has been proven effective against the disease. It has been shown that patient with a late onset of h-ATTR amyloidosis have high levels of circulating auto-antibodies against miss-folded amyloidogenic TTR. It is therefore reasonable to suspect, that circulating antibodies against miss-folded TTR are part of the natural defence system against circulating amyloidogenic TTR. Since we have a large population of predominantly late onset h-ATTR amyloidosis patients, and also healthy carriers of the TTR V30M mutation, we are able to collect blood samples for identification of antibodies with a high affinity for miss-folded TTR and low affinity for wild type TTR. This should enable a development of antibody treatment of both wt- and h- ATTR amyloidosis, aiming at a vital substrate for amyloid formation, i.e., miss-folded TTR.

**Further information available at:**

**Types:**

Investments < €500k

**Member States:**

Sweden

**Diseases:**

N/A

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A